Skip to main content


Cancer Research Journal

Dr. Shweta Joshi's group shows a FDA-approved Syk inhibitor (Fostamatinib) can reprogram macrophages, enhance the anti-tumor immune response, and improve the efficacy of Gemcitabine in pancreatic cancer. 

Curebound Discovery Grant

Joshi lab received a competitive Discovery grant award from Cure bound. This funding will allow us to develop novel therapeutic approaches to improve immunotherapy efficacy in high-risk neuroblastoma. .

Postdoc Positions Available: 

Currently seeking highly motivated and dedicated postdoctoral fellows with experience in immunology, oncology, cell biology, and molecular biology. Please send your updated resume and three references to Shweta Joshi,

July 2021

Joshi lab received a five-year $ 2.0M R01 grant from NIH.

August 2020

Dr. Joshi’s Lab got funds from “Padres Pedal the Cause” to develop novel immunotherapies for neuroblastoma.